SJSuzanne Bennett Johnson

Suzanne Bennett Johnson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Suzanne Bennett Johnson has a total of 230 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Psychological Impact of Screening for Risk of Type 1 Diabetes: an Update

    by Suzanne Bennett Johnson, Holly O’dOnnell, Laura B. Smith, Jessica Melin

    Purpose of Review Summarize recent literature on: understanding of and emotional reactions to type 1 diabetes (T1D) risk; willingness to be screened; behavioral responses to T1D-risk screening results; and provider attitudes/concerns about general population screening. Recent Findings Difficulty understanding what it means to be at increased risk for T1D is common; anxiety about increased risk may occur, particularly in multiple islet autoantibody positive (IA+) individuals. Many are hesitant to be screened or to be medically monitored if at increased risk. Those at risk may engage in behaviors to try to prevent T1D. Providers are often cautious about general population screening, with concerns about associated anxiety paramount. Summary Understanding the psychosocial implications of T1D-risk screening is critical to its success. Interventions are needed to improve understanding of the purpose, procedures and consequences of screening, what it means to be at risk, and ways to cope with associated anxiety. The psychosocial impact of a Stage 1 or Stage 2 T1D diagnosis needs clarification and the availability of drugs to delay disease onset is likely to have a significant impact on the decision to be screened and monitored if at-risk for T1D. The impact of screening on children as well as their role in screening/medical monitoring decision-making needs to be addressed.


  • The Use of Continuous Glucose Monitoring to Diagnose Stage 2 Type 1 Diabetes

    by Julia K. Mader, Jenise C. Wong, Guido Freckmann, Jose Garcia-Tirado, Irl B. Hirsch, Suzanne Bennett Johnson, David Kerr, Sun H. Kim, Rayhan Lal, Eslam Montaser, et al.

    This consensus report evaluates the potential role of continuous glucose monitoring (CGM) in screening for stage 2 type 1 diabetes (T1D). CGM offers a minimally invasive alternative to venous blood testing for detecting dysglycemia, facilitating early identification of at-risk individuals for confirmatory blood testing. A panel of experts reviewed current evidence and addressed key questions regarding CGM’s diagnostic accuracy and screening protocols. They concluded that while CGM cannot yet replace blood-based diagnostics, it holds promise as a screening tool that could lead to earlier, more effective intervention. Metrics such as time above range >140 mg/dL could indicate progression risk, and artificial intelligence (AI)-based modeling may enhance predictive capabilities. Further research is needed to establish CGM-based diagnostic criteria and refine screening strategies to improve T1D detection and intervention.


  • Children’s Understanding of Risk for Type 1 Diabetes: The TEDDY Study

    by Holly O’DOnnell, Roy Tamura, Laura Smith, Kimberly Driscoll, Jessica Melin, Kimber Simmons, Suzanne Bennett Johnson

    This study, part of the ongoing TEDDY (The Environmental Determinants of Diabetes in the Young) study, assessed children’s understanding of their own risk for type 1 diabetes from 10 to 15 years of age and sought to identify factors associated with children’s risk perception. Analysis of responses from nearly 5,000 children revealed that risk for type 1 diabetes is a difficult concept for children to grasp even in the context of extensive educational efforts. Several factors associated with children’s understanding of type 1 diabetes risk were identified that may guide future efforts to help children understand disease risk.


  • Open Access

    Structures and strategies for retaining an international pediatric cohort from birth: Lessons from The Environmental Determinants of Diabetes in the Young (TEDDY) study

    by Patricia Gesualdo, Jessica Melin, Rachel Karban, Claire Crouch, Michael Killian, Diane Hopkins, Annika Adamsson, Joanna Stock, Suzanne Bennett Johnson, Judith Baxter


  • Looking back at the TEDDY study: lessons and future directions

    by Åke Lernmark, Daniel Agardh, Beena Akolkar, Patricia Gesualdo, William A. Hagopian, Michael J. Haller, Heikki Hyöty, Suzanne Bennett Johnson, Helena Elding Larsson, Edwin Liu, et al.

    The goal of the TEDDY (The Environmental Determinants of Diabetes in the Young) study is to elucidate factors leading to the initiation of islet autoimmunity (first primary outcome) and those related to progression to type 1 diabetes mellitus (T1DM; second primary outcome). This Review outlines the key findings so far, particularly related to the first primary outcome. The background, history and organization of the study are discussed. Recruitment and follow-up (from age 4 months to 15 years) of 8,667 children showed high retention and compliance. End points of the presence of autoantibodies against insulin, GAD65, IA-2 and ZnT8 revealed the HLA-associated early appearance of insulin autoantibodies (1–3 years of age) and the later appearance of GAD65 autoantibodies. Competing autoantibodies against tissue transglutaminase (marking coeliac disease autoimmunity) also appeared early (2–4 years). Genetic and environmental factors, including enterovirus infection and gastroenteritis, support mechanistic differences underlying one phenotype of autoimmunity against insulin and another against GAD65. Infant growth and both probiotics and high protein intake affect the two phenotypes differently, as do serious life events during pregnancy. As the end of the TEDDY sampling phase is approaching, major omics approaches are in progress to further dissect the mechanisms that might explain the two possible endotypes of T1DM.


  • Open Access

    Correction to: Consensus guidance for monitoring individuals with islet autoantibody‑positive pre‑stage 3 type 1 diabetes

    by Moshe Phillip, Peter Achenbach, Ananta Addala, Anastasia Albanese‑O’nEill, Tadej Battelino, Kirstine J. Bell, Rachel E. J. Besser, Ezio Bonifacio, Helen M. Colhoun, Jennifer J. Couper, et al.


  • Top Cited Papers
    Open Access

    Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes

    by Moshe Phillip, Peter Achenbach, Ananta Addala, Anastasia Albanese-O’neill, Tadej Battelino, Kirstine J. Bell, Rachel E.J. Besser, Ezio Bonifacio, Helen M. Colhoun, Jennifer J. Couper, et al.

    Given the proven benefits of screening to reduce diabetic ketoacidosis (DKA) likelihood at the time of stage 3 type 1 diabetes diagnosis, and emerging availability of therapy to delay disease progression, type 1 diabetes screening programs are being increasingly emphasized. Once broadly implemented, screening initiatives will identify significant numbers of islet autoantibody–positive (IAb+) children and adults who are at risk for (confirmed single IAb+) or living with (multiple IAb+) early-stage (stage 1 and stage 2) type 1 diabetes. These individuals will need monitoring for disease progression; much of this care will happen in nonspecialized settings. To inform this monitoring, JDRF, in conjunction with international experts and societies, developed consensus guidance. Broad advice from this guidance includes the following: 1) partnerships should be fostered between endocrinologists and primary care providers to care for people who are IAb+; 2) when people who are IAb+ are initially identified, there is a need for confirmation using a second sample; 3) single IAb+ individuals are at lower risk of progression than multiple IAb+ individuals; 4) individuals with early-stage type 1 diabetes should have periodic medical monitoring, including regular assessments of glucose levels, regular education about symptoms of diabetes and DKA, and psychosocial support; 5) interested people with stage 2 type 1 diabetes should be offered trial participation or approved therapies; and 6) all health professionals involved in monitoring and care of individuals with type 1 diabetes have a responsibility to provide education. The guidance also emphasizes significant unmet needs for further research on early-stage type 1 diabetes to increase the rigor of future recommendations and inform clinical care.


  • Open Access

    Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes

    by Moshe Phillip, Peter Achenbach, Ananta Addala, Anastasia Albanese-O’nEill, Tadej Battelino, Kirstine J. Bell, Rachel E. J. Besser, Ezio Bonifacio, Helen M. Colhoun, Jennifer J. Couper, et al.

    Given the proven benefits of screening to reduce diabetic ketoacidosis (DKA) likelihood at the time of stage 3 type 1 diabetes diagnosis, and emerging availability of therapy to delay disease progression, type 1 diabetes screening programmes are being increasingly emphasised. Once broadly implemented, screening initiatives will identify significant numbers of islet autoantibody-positive (IAb+) children and adults who are at risk of (confirmed single IAb+) or living with (multiple IAb+) early-stage (stage 1 and stage 2) type 1 diabetes. These individuals will need monitoring for disease progression; much of this care will happen in non-specialised settings. To inform this monitoring, JDRF in conjunction with international experts and societies developed consensus guidance. Broad advice from this guidance includes the following: (1) partnerships should be fostered between endocrinologists and primary-care providers to care for people who are IAb+; (2) when people who are IAb+ are initially identified there is a need for confirmation using a second sample; (3) single IAb+ individuals are at lower risk of progression than multiple IAb+ individuals; (4) individuals with early-stage type 1 diabetes should have periodic medical monitoring, including regular assessments of glucose levels, regular education about symptoms of diabetes and DKA, and psychosocial support; (5) interested people with stage 2 type 1 diabetes should be offered trial participation or approved therapies; and (6) all health professionals involved in monitoring and care of individuals with type 1 diabetes have a responsibility to provide education. The guidance also emphasises significant unmet needs for further research on early-stage type 1 diabetes to increase the rigour of future recommendations and inform clinical care. Graphical Abstract


  • Open Access

    General Population Screening for Islet Autoantibodies: Psychosocial Challenges

    by Suzanne Bennett Johnson, Laura B. Smith

    In recent years, general population screening for islet antibodies (IA) has become more common. However, there are notable challenges to implementing general po


  • The association of physical activity to oral glucose tolerance test outcomes in multiple autoantibody positive children: The TEDDY Study

    by Suzanne Bennett Johnson, Roy Tamura, Kerry L. McIver, Russell R. Pate, Kimberly A. Driscoll, Jessica Melin, Helena Elding Larsson, Michael J. Haller, Jimin Yang, the TEDDY Study Group

    Objective To examine the association of physical activity (PA), measured by accelerometry, to hemoglobin AIC (HbA1c) and oral glucose tolerance test (OGTT) outcomes in children who were multiple persistent confirmed autoantibody positive for type 1 diabetes (T1D). Methods The Environmental Determinants of Diabetes in the Young (TEDDY) multinational study followed children from birth. Children >= 3 years of age who were multiple persistent confirmed autoantibody positive were monitored by OGTTs every 6 months. TEDDY children's PA was measured by accelerometry beginning at 5 years of age. We examined the relationship between moderate plus vigorous (mod + vig) PA, HbA1c, and OGTT in 209 multiple autoantibody children who had both OGTT and PA measurements. Results Mod + vig PA was associated with both glucose and C-peptide measures (fasting, 120-min, and AUC); higher mod + vig PA was associated with a better OGTT response primarily in children with longer duration of multiple autoantibody positivity. Mod + vig PA also interacted with child age; lower mod + vig PA was associated with a greater increase in C-peptide response across age. Mod + vig PA was not related to fasting insulin, HOMA-IR or HbA1c. Conclusions The OGTT is the gold standard for diabetes diagnosis and is used to monitor those at high risk for T1D. We found higher levels of mod + vig PA were associated with better OGTT outcomes in children >= 5 years of age who have been multiple autoantibody positive for longer periods of time. Physical activity should be the focus of future efforts to better understand the determinants of disease progression in high-risk children.